Mesoblast (MESO) Capital Expenditures (2022 - 2023)

Mesoblast (MESO) posted quarterly Capital Expenditures of $214000.0 for Q2 2023, up 336.73% on a QoQ basis from $49000.0 in Q1 2022.

Mesoblast (MESO) Capital Expenditures (2022 - 2023) Analysis & Trends

Mesoblast (MESO) has reported Capital Expenditures for 2 consecutive years, with $214000.0 the latest figure, recorded in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Mesoblast	2.08 Bn	1.95 Bn	-	-

Download Data